Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

Drug executives talked M&A and the incoming administration, but also weighed the outlook for cell and gene therapy developers ...

Regulatory complexity isn’t the only challenges clinical services organizations face in the APAC market. Cheong points to ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...